Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [123I]IBZM SPECT

Psychiatry Research - Neuroimaging

Volumn 173, Issue 3, 2009, Pages 183-189

  Schmitt, Gisela Johanna Elisabeth ^a   Meisenzahl, Eva Maria ^a   Frodl, Thomas ^a   La Fougère, Christian ^a   Hahn, Klaus ^a   Möller, Hans Jürgen ^a   Dresel, Stefan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acute psychotic syndrome; Hallucinations; Striatal dopamine D2 receptor

Indexed keywords

DOPAMINE 2 RECEPTOR; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; RADIOLIGAND;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DELUSION; DISEASE EXACERBATION; DOPAMINERGIC TRANSMISSION; FEMALE; HALLUCINATION; HUMAN; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; BENZAMIDES; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MALE; PROTEIN BINDING; PSYCHIATRIC STATUS RATING SCALES; PYRROLIDINES; SCHIZOPHRENIA; STATISTICS AS TOPIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 68949201463     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2008.11.001     Document Type: Article

References (43)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., van Dyck C.H., Charney D.S., Innis R.B., and Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. American Journal of Psychiatry 155 (1998) 761-767
2. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., Weiss R., Cooper T.B., Mann J.J., Van Heertum R.L., Gorman J.M., and Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences 97 (2000) 8104-8109
3. Åsberg M., Montgomery S.A., Perris C., Schalling D., and Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatrica Scandinavica. Supplementum 271 (1978) 5-27
4. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., and Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America 94 (1997) 2569-2574
5. Buchsbaum M.S., Christian B.T., Lehrer D.S., Narayanan T.K., Shi B., Mantil J., Kemether E., Oakes T.R., and Mukherjee J. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophrenia Research 85 (2006) 232-244
6. Carlsson A., and Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica 20 (1963) 140-144
7. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., and Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annual Review of Pharmacology and Toxicology 41 (2001) 237-260
8. Copolov D.L., Seal M.L., Maruff P., Ulusoy R., Wong M.T.H., Tochon-Danguy H.J., and Egan G.F. Cortical activation associated with the experience of auditory hallucinations and perception of human speech in schizophrenia: a PET correlation study. Psychiatry Research. Neuroimaging 122 (2003) 139-152
9. Creese I., Burt D.R., and Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 19 (1976) 481-483
10. Dresel S., Tatsch K., Dahne I., Mager T., Scherer J., and Hahn K. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients. Journal of Nuclear Medicine 39 (1998) 1138-1142
11. Dresel S., Mager T., Rossmuller B., Meisenzahl E., Hahn K., Moller H.J., and Tatsch K. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. European Journal of Nuclear Medicine 26 (1999) 862-868
12. 2 receptor increase in PET study of schizophrenia. Archives of General Psychiatry 44 (1987) 671-672
13. 11C]Raclopride. Archives of General Psychiatry 47 (1990) 213-219
14. Halligan P.W., and David A.S. Cognitive neuropsychiatry: towards a scientific psychopathology. Nature Reviews. Neuroscience 2 (2001) 209-215
15. 2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Archives of General Psychiatry 51 (1994) 116-123
16. Hubl D., Koenig T., Strik W., Federspiel A., Kreis R., Boesch C., Maier S.E., Schroth G., Lovblad K., and Dierks T. Pathways that make voices. Archives of General Psychiatry 61 (2004) 658-668
17. Ichise M., Ballinger J.R., Tanaka F., Moscovitch M., St. George-Hyslop P.H., Raphael D., and Freedman M. Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT. Journal of Nuclear Medicine 39 (1998) 1511-1518
18. Johns L.C., and McGuire P.K. Verbal self-monitoring and auditory hallucinations in schizophrenia. Lancet 353 (1999) 469-470
19. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13 (1987) 261-276
20. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. Journal of Cerebral Blood Flow and Metabolism 20 (2000) 423-451
21. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C.L., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., and Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences 93 (1996) 9235-9240
22. Leysen J.E., Van Gompel P., de Chaffoy de Courcelles D., and Niemegeers C.J. Opposite regulation of serotonin-S2 and dopamine-D2 receptors in rat brain following chronic receptor blockade. Journal of Receptor Research 7 (1987) 223-239
23. McGuire P.K., Silbersweig D.A., Wright I., Murray R.M., David A.S., Frackowiak R.S., and Frith C.D. Abnormal monitoring of inner speech: a physiological basis for auditory hallucinations. Lancet 346 (1995) 596-600
24. McGuire P.K., Silbersweig D.A., Wright I., Murray R.M., Frackowiak R.S., and Frith C.D. The neural correlates of inner speech and auditory verbal imagery in schizophrenia: relationship to auditory verbal hallucinations. British Journal of Psychiatry 169 (1996) 148-159
25. Meisenzahl E.M., Dresel S., Frodl T., Schmitt G.J., Preuss U.W., Rossmuller B., Tatsch K., Mager T., Hahn K., and Möller H.J. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. Journal of Psychopharmacology 14 (2000) 364-370
26. Möller H.J. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Progress in Neuro-psychopharmacology & Biological Psychiatry 27 (2003) 1101-1111
27. Mombour K., Kockott G., and Fliege K. The use of the brief psychiatric rating scale (BPRS) by overall and gorham for the diagnosis of acute paranoid psychoses: evaluation of a German translation of the BPRS (author's transl). Pharmakopsychiatrie, Neuro-Psychopharmakologie 8 (1975) 279-288
28. Montgomery S., Åsberg M., Jornestedt L., Thoren P., Traskman L., McAuley R., Montgomery D., and Shaw P. Reliability of the CPRS between the disciplines of psychiatry, general practice, nursing and psychology in depressed patients. Acta Psychiatrica Scandinavica. Supplementum 271 (1978) 29-32
29. Mukherjee J., Christian B.T., Dunigan K.A., Shi B., Narayanan T.K., Satter M., and Manti J. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 46 (2002) 170-188
30. Pilowsky L.S., Costa D.C., Ell P.J., Verhoeff N.P., Murray R.M., and Kervin R.W. Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone. British Journal Psychiatry 163 (1994) 833-834 (Erratum in: Br J Psychiatry 1994 Feb;164:270)
31. 2 receptor binding characteristics in vivo. American Journal of Psychiatry 155 (1998) 768-773
32. Schmitt G.J., Meisenzahl E.M., Dresel S., Tatsch K., Rossmuller B., Frodl T., Preuss U.W., Hahn K., and Moller H.J. Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine. Journal of Psychopharmacology 16 (2002) 200-206
33. Seeman P., and Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188 (1975) 1217-1219
34. Shergill S.S., Bullmore E., Simmons A., Murray R.M., and McGuire P.K. Functional anatomy of auditory verbal imagery in schizophrenic patients with auditory hallucinations. American Journal of Psychiatry 157 (2000) 1691-1693
35. Shergill S.S., Brammer M.J., Williams S.C.R., Murray R.M., and McGuire P.K. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Archives of General Psychiatry 57 (2000) 1033-1038
36. Shergill S.S., Brammer M.J., Fukuda R., Williams S.C.R., Murray R.M., and McGuire P.K. Engagement of brain areas implicated in processing inner speech in people with auditory hallucinations. British Journal of Psychiatry 182 (2003) 525-531
37. Shergill S.S., Brammer M.J., Amaro E., Williams S.C.R., Murray R.M., and McGuire P.K. Temporal course of auditory hallucinations. British Journal of Psychiatry 185 (2004) 516-517
38. Silbersweig D.A., Stern E., Frith C., Cahill C., Holmes A., Grootoonk S., Seaward J., McKenna P., Chua S.E., Schnorr L., Jones T., and Frackowiak R.S.J. A functional neuroanatomy of hallucinations in schizophrenia. Nature 378 (1995) 176-179
39. Slade P., and Bentall R. Sensory Deception: A Scientific Analysis of Hallucination (2002), Croom Helm, London, England
40. 2 receptor binding in the anterior cingulate cortex in schizophrenia. Archives of General Psychiatry 59 (2002) 25-30
41. van Rossum J.M. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Brill H., Cole J.O., Deniker P., Hippius H., and Bradley P.B. (Eds). Proceedings of the Fifth Collegium Internationale Neuropsychopharmacologicum (1967), Excerpta Medica, Amsterdam 321-329
42. Vollenweider F.X., and Geyer M.A. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Research Bulletin 56 (2001) 495-507
43. Yasuno F., Suhara T., Okubo Y., Sudo Y., Inoue M., Ichimiya T., Takano A., Nakayama K., Halldin C., and Farde L. Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. American Journal of Psychiatry 161 (2004) 1016-1022